Announced details
BNCT, cancer treatment, and the introduction of BNCT at medical institutions
Following a request for cooperation from CBSH, the Company is collaborating with SUMITOMO HEAVY INDUSTRIES,LTD. on activities to disseminate information on and promote BNCT. The Company has collaborative relationships with CBSH and Pengbo, including in the BNCT business in the Hainan Bo'ao Lecheng International Medical Tourism Pilot Zone.
CBSH is listed on the Hong Kong Stock Exchange under stock code 8037. Other details of Pengbo are Not disclosed. Details of SUMITOMO HEAVY INDUSTRIES,LTD. are Not disclosed.
Shanghai, China (CIIE venue)
No disclosure has been made regarding the impact on financial results: Not disclosed
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Pharmaceuticals for BNCT, Panboron BNCT |
| Counterparty | China Biotech Services Holdings Limited (Hong Kong Stock Exchange stock code: 8037), Pengbo, SUMITOMO HEAVY INDUSTRIES,LTD. |
| Counterparty overview | CBSH is listed on the Hong Kong Stock Exchange under stock code 8037. Other details of Pengbo are Not disclosed. Details of SUMITOMO HEAVY INDUSTRIES,LTD. are Not disclosed. |
| Relationship with the Company | Following a request for cooperation from CBSH, the Company is collaborating with SUMITOMO HEAVY INDUSTRIES,LTD. on activities to disseminate information on and promote BNCT. The Company has collaborative relationships with CBSH and Pengbo, including in the BNCT business in the Hainan Bo'ao Lecheng International Medical Tourism Pilot Zone. |
| Launch date | 5–10 November 2026 (participation in the CIIE) |
| Applicable area | BNCT, cancer treatment, and the introduction of BNCT at medical institutions |
| Location | Shanghai, China (CIIE venue) |
| Impact on Business Performance | No disclosure has been made regarding the impact on financial results: Not disclosed |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To disseminate information on BNCT in China, promote its adoption, and strengthen relationships with local medical professionals and others. In addition, BNCT adoption in mainland China is viewed as an important growth opportunity.